In recent years, numerous reports have tied cytomegalovirus retinitis (CMVR) with multiple systemic conditions in the absence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). These range from reports in apparently healthy individuals, through conditions rendering limited immune dysfunction such as advanced age and diabetes mellitus, and finally severe immune dysfunction such as in haematological and rheumatological conditions. Reports are also emerging, suggesting that induced local ocular immunosuppression is a risk factor for CMVR. We herein present a comprehensive collection of the accumulated findings regarding CMVR in non-HIV patients. We summarize the spectrum of underlying morbidity that has been associated with CMVR, its clinical presentation, diagnostic methods and treatment choice in the attempt to suggest the optimal treatment strategy in this complicated and diverse patient population which is still currently lacking a consensus.
Introduction
Classically CMVR has been associated with AIDS, and before the advent of highly active retroviral therapy up to 40% of these patients were affected (Palestine et al. 1984) . Nevertheless, modern immunosuppressive therapies as well as improved survival rates have in recent years increased the incidence of opportunistic infections in other patient populations, and reports of CMVR in HIV-negative patients have been accumulating (Derzko-Dzulynsky et al. 1998; Bertelmann et al. 2005; Chawla et al. 2005; Delyfer et al. 2007; Sloan et al. 2008; Jeon et al. 2012; Bae et al. 2013; Davis et al. 2013; Gupta et al. 2013; Radwan et al. 2013; Samia et al. 2014; Jeon & Lee 2015; Vishnevskia-Dai et al. 2015; Downes et al. 2016; Iu et al. 2016; Karkhaneh et al. 2016) .
Despite the recent rise in reported cases, to date there is no consensus regarding the optimal treatment strategy in this complicated and diverse patient population, including choosing a method for prompt diagnosis, antiviral therapy and its delivery modality (e.g. systemic versus intravitreal) (Miao et al. 2013) . This is especially vague regarding the paediatric population (Hansen et al. 1994; Mota et al. 2011; Kobayashi et al. 2012; Singh et al. 2012; Moritake et al. 2013; Wakai et al. 2013; Samia et al. 2014 ).
In the current review, we attempted to compile the accumulated data regarding CMVR in non-HIV-infected patients. Particularly, we focused on CMVR reported in healthy, autoimmune/rheumatic or onco-haematological patients.
Materials and Methods
We conducted a MEDLINE search for all English language publications between 1995 and 2016 using the following keywords in various combinations: 'cytomegalovirus', 'retinitis', 'healthy', 'HIV negative', 'non-HIV', 'haematological', 'stem cell transplant', 'autoimmune' and 'rheumatic'. Indexed reports retrieved by this search were included, with the exception of reports concerning solid organ transplant cases. Data regarding systemic condition and immune status, immunomodulatory therapy, CMVR diagnosis strategy, antiviral therapy and outcome are summarized in Tables S1  and S2. summarized in Box 1, these range from reports in apparently healthy individuals, through conditions rendering limited immune dysfunction such as advanced age, diabetes mellitus, hypertension, renal insufficiency and finally severe systemic immune dysfunction.
A total of 170 reported cases were retrieved for this review (see Tables S1  and S2 ). The majority are single-case reports or retrospective case-series, of these four are interventional (Miao et al. 2013; Jeon & Lee 2015; Vishnevskia-Dai et al. 2015; Iu et al. 2016) . A total of 142 CMVR cases have been associated with systemic immune dysfunction (Table S1 ). Almost 90% (n = 126) were reported since 2010, of which 58% (n = 82) cases were male, and the average adult age at onset was 50.3 AE 17.6 years (range, 17-89 years). In the 16 reported paediatric cases, the average age at onset was 7.8 AE 5.9 years (range, 3 months-15 years).
The additional 28 cases are tied with local immune suppression (Table S2) , all reported in the last decade, and almost 80% (n = 22) were reported since 2010; 64% (n = 18) were male, and the average age at onset was 66.7 AE 12.1 years (range, 30-84 years).
The Role of Limited Immune Dysfunction
It seems that awareness is being raised particularly regarding the diabetic patient population, as those previously exposed to cytomegalovirus (CMV) are at risk of CMVR both systemically and in some cases also locally when treated with intravitreal steroids. This comorbidity was previously noted in up to 50% of otherwise immunocompetent patients who developed CMVR (Takakura et al. 2014) . Diabetic rats exhibit increased leucocyte entrapment due to alterations of leucocyte properties and microvasculature changes in diabetic retinopathy; thus, it was speculated that leucocytes latently infected with CMV can become entrapped in their retina, causing CMVR to occur despite apparent immunocompetence (Miyamoto et al. 1998; Yoshinaga et al. 2008; Toyokawa et al. 2010; Radwan et al. 2013 ). This mechanism may play a role in CMVR activation in other hypercoagulable states including hypertension (Radwan et al. 2013) . Furthermore, intravitreal injection of steroids might activate leucocytes latently infected with CMV in the retina (Toyokawa et al. 2010) .
Evidence suggests that the elderly, with associated morbidities, might represent a large population at risk for CMVR with few apparent additional risk factors (Davis et al. 2013) . Taken together, designation of patients as immunocompetent or immunocompromised should take into consideration a grey zone with regards to risk of acquiring CMVR.
CMVR in Non-HIVRelated Systemic Immunosuppression
The risk of CMVR in clear immunocompromise, and primarily after hematopoietic stem cell transplantation (HSCT), shows a trend of increase during the past decade (Miao et al. 2013 ) (see Table S1 ). Jeon et al. (2012) evaluated risk factors for CMVR in a cohort of patients with CMV viremia following HSCT. Factors related to immune status; viral loads, including peak CMV DNA level; and duration of viremia were related to the development of CMVR. In a recent interventional series (Vishnevskia-Dai et al. 2015) , we reported that the majority of cases (6/9) contracted the disease during or soon after systemic immunosuppressive treatment associated with bone marrow transplantation (BMT) due to underlying haematological or immunological morbidity. The remaining three cases suffered from immune dysfunction either due to severe combined immune deficiency (SCID), diabetes mellitus or diabetes mellitus as well as multiple myeloma comorbidity. Furthermore, the latter two patients had also received high-dose intravitreal triamcinolone acetonide (IVTA) injections. Table S2 summarizes the accumulating reports of CMVR in locally immunocompromised eyes, unsurprisingly with an almost exclusive unilateral involvement in these cases. The primary culprit is IVTA, with administered doses ranging from 4 to 20 mg (Saidel et al. 2005; Park & Byeon 2008; Sekiryu et al. 2008; Vishnevskia-Dai et al. 2015) . It is apparent that a higher dose of IVTA remains in the vitreous for a longer period of time, and is therefore of benefit in long-standing diseases such as severe diabetic macular oedema (Delyfer et al. 2007 ). Yet, it may come with the risk of prolonged local immunosuppression and susceptibility to primary infection or reactivation of endogenous latent viral retinitis (Delyfer et al. 2007 ). Subtenon administration of triamcinolone (TA) has also been implicated, with administered doses ranging from 20 to 40 mg (Toyokawa et al. 2010; Davis et al. 2013; Takakura et al. 2014) . Interestingly, the potential contribution of vascular endothelial growth factor inhibitors to the local immunosuppressive effect of steroids has been suggested (Toyokawa et al. 2010; Gupta et al. 2013) . Finally, there are anecdotal reports of CMVR following fluocinolone acetonide implant (UfretVincenty et al. 2007; Takakura et al. 2014 ) and following 0.05% cyclosporin eye drops (Toriyama et al. 2012) .
CMVR in Local Immunocompromise

From Immunosuppression to Presentation of CMVR
In a series of 15 patients who developed CMVR following HSCT (Jeon et al. 2012) , CMV viremia was detected at a mean of 5.2 weeks (range, 3-14 weeks) after HSCT, and CMVR developed at a mean of 13.5 weeks (range, 4-36 weeks) after detection of CMV viremia, which was a mean of 18.7 weeks (range, 7-39 weeks) after HSCT. Similarly, in our series (Vishnevskia-Dai et al. 2015) , the median time to CMVR diagnosis in 5 postbone marrow transplanted patients was 5 months. The interval to diagnosis in our immunosuppressed paediatric cases was 2.5 months or less from BMT or initiation of chemotherapy.
In a recent series of 9 Korean HIVnegative patients with CMVR, all patients received systemic treatment for CMV viremia upon diagnosis and their retinitis was diagnosed by routine ophthalmologic screening (Jeon & Lee 2015) . Similarly in our medical centre, patients undergoing BMT are routinely screened twice weekly for systemic CMV-PCR. In all positive cases, immediate preemptive systemic antiviral therapy is administered. Therefore, in our series, all BMT patients were under systemic antiviral treatment when diagnosed (Vishnevskia-Dai et al. 2015) .
The interval between IVTA and CMVR is typically 3-7 months (Cho et al. 2012) , although it can occur as early as 1 month following treatment (Takakura et al. 2014; Vishnevskia-Dai et al. 2015) .
Clinical Presentation of CMVR in the Absence of HIV
It has been suggested that patients without HIV infection demonstrate more variable clinical presentation than classic CMVR observed in HIVpositive patients (Davis et al. 2013; Pathanapitoon et al. 2013; Schneider et al. 2013 ). In typical HIV-related CMVR, inflammatory vascular involvement is usually limited to nonocclusive venous sheathing in areas of retinitis. Aqueous and vitreous inflammation is usually mild, especially in relation to the extent of associated retinitis (Schneider et al. 2013) . Schneider et al. (2013) reported five patients with non-HIV-related CMVR displaying a different clinical phenotype. Although characteristic granular retinitis was present in all cases, panretinal occlusive vasculitis -involving areas distant from the associated retinitiswas the predominant manifestation. Additionally, the degree of intraocular inflammation was relatively severe in comparison with the limited extent of retinitis (Schneider et al. 2013) . Pathanapitoon et al. (2013) have similarly reported that in their Thai patient population, all HIV-negative CMVR patients exhibited associated vitreous inflammation (22/22 eyes) and that 64% of eyes developed an anterior chamber inflammatory reaction. The presence of retinal vasculitis was a common characteristic (73%), predominantly involving arteries. The retinal features resembled in part the classic HIV-associated manifestations, described as haemorrhagic and granular types of retinitis, but these cases also included manifestations typical of acute retinal necrosis (ARN), as well as retinal vasculitis associated with vitritis (Pathanapitoon et al. 2013 ). Davis et al. have likewise claimed that CMVR in non-HIV-infected elderly patients is associated with retinal arteriolar occlusions (Davis et al. 2013) hypothesizing that, in contrary to patients with AIDS, immunity generates more prominent tissue damage (Davis et al. 2013; Schneider et al. 2013) .
Recently, in a series of 13 patients (20 involved eyes) described by Iu et al. (Iu et al. 2016) , an aggressive presentation was often noted. 50% presented with visual acuity (VA) <20/70 and 25% with VA <20/400. Zone 1 involvement occurred in 55% of eyes, an extent of 11-25% retinal area involvement occurred in 50%, presence of vitreous haze in 55% and retinal vasculitis was present in 70% of eyes (Iu et al. 2016) .
In our recent series, the most prevalent ocular findings at presentation were vasculitis (94%), retinal haemorrhages (69%) and keratic precipitates (KPS) (38%). However, in our series only 12.5% had anterior chamber cells and only 6% had vitritis at diagnosis (Vishnevskia-Dai et al. 2015) .
Diagnosis of CMVR
Typically, confirmation of CMVR diagnosis can be achieved by obtaining an aqueous or vitreous sample, in which CMV may be detected by PCR (Fox et al. 1991; Derzko-Dzulynsky et al. 1998) . It seems that centres are divided into their preference for either aqueous (24 centres) or vitreous tap (24 centres; see Tables S1 and S2). Iu et al. (2016) reported that aqueous humour PCR was positive in 16 of 18 tested eyes (89%). All 13 patients in their series underwent blood tests, either CMV pp65 antigenemia assays or CMV PCR analysis, and nine patients showed positive results (69%).
We similarly advocate a more widespread use of the aqueous PCR approach, as we believe it should simplify the diagnosis without the need for invasive posterior diagnostic procedure in these complicated patients and should be performed in adults for definitive prompt diagnosis (Vishnevskia-Dai et al. 2015) .
The diagnosis of CMVR in children is challenging because of absence of external ocular signs or inability to express visual symptoms. These factors along with a more aggressive nature of retinitis and tendency towards bilateral involvement pose a serious risk of irreversible blindness warranting special attention and prompt initiation of treatment (Mota et al. 2011; Singh et al. 2012) . Baring this in mind, and as aqueous tap procedure in children is performed under general anaesthesia, we recommend to reserve it for Box 2: Suggested treatment algorithm for CMV retinitis in HIV-negative patients* AC = anterior chamber, ARN = acute retinal necrosis, CSF = cerebrospinal fluid, HSV = herpes simplex virus, HIV = human immunodeficiency virus, PCR = polymerase chain reaction, VZV = varicella zoster virus. * Adopted with permission from Vishnevskia-Dai et al. (2015) . 1 Intravitreal injections should be given as loading doses 2-3 times per week followed by maintenance dosing once a week (ganciclovir intravitreal induction dosage -2 mg/0.1 ml; foscarnet intravitreal induction dosage -2.4 mg/0.1 ml). 2 In case effective dose of intravenous treatment is contraindicated (e.g. neutropenia; renal failure), consider adding or switching to intravitreal agent (ganciclovir or foscarnet). 3 In case AC tap confirmation was not performed, execute AC tap confirmation at this time.
paediatric cases that do not improve with systemic treatment alone and to postpone the procedure until concomitant intravitreal treatment is warranted.
There is a strong association between CMV viremia as well as CMV DNAemia (PCR) in serum and CMVR (Hansen et al. 1994; Freeman 1996; Fezza et al. 2001; Iu et al. 2016) . Furthermore, systemic testing methods for CMV are routinely used to monitor patients for reactivation and response to treatment in the haematological settings. Thus, we have previously suggested based on our experience (Vishnevskia-Dai et al. 2015 ) that a clinical diagnosis of retinitis supported by blood and/or CSF evidence of CMV should prompt immediate therapy. There are other centres reporting confirmation of CMVR based on systemic testing (Mota et al. 2011; Jeon et al. 2012; Kobayashi et al. 2012; Davis et al. 2013; Samia et al. 2014; Iu et al. 2016) . Notwithstanding, definitive diagnosis should preferably be achieved in all cases when possible.
Treatment and Outcome
The commonly used systemic antiviral ganciclovir requires hospitalization for IV administration. It is associated with frequent neutropenia, and dosage must be decreased in the setting of renal failure, neutropenia or thrombocytopenia, all commonly encountered conditions in patients with severe systemic morbidity, and particularly myelosuppression (Song et al. 2008; Miao et al. 2013) . Further disadvantages of intravenous antiviral delivery include decreased bioavailability in ocular tissues requiring prolonged treatment (Singh et al. 2012) .
Consequently, intravitreal drug delivery modalities incorporating ganciclovir or foscarnet injections have emerged as alternatives, in some cases as first line if systemic infection has been ruled out (Langner-Wegscheider et al. 2010; Mota et al. 2011; Singh et al. 2012) . Intravitreal ganciclovir and foscarnet are also indicated when patients are intolerant or unresponsive to systemic therapy, and they offer introduction of a higher concentration of the drug directly to the target organ -the retina (Sun et al. 2012) .
Repeated doses ranging from 200 lg/0.1 ml to 2000 lg/0.1 ml had been proved to be safe for intravitreal injection, but cumulative 40 mg resulted in retinal damage (Miao et al. 2013) . The most commonly used intravitreal dosages are 2 mg/0.1 ml for ganciclovir and 2.4 mg/0.1 ml for foscarnet (Jeon & Lee 2015; Vishnevskia-Dai et al. 2015 ).
An intravitreal ganciclovir implant, which is effective for 6-9 months, was reported to be effective for controlling HIV-related CMV retinitis (Oktavec et al. 2012) . While several centres report using an implant for treatment of non-HIV-related CMVR (Bertelmann et al. 2005; Ufret-Vincenty et al. 2007; Hoang et al. 2010; LangnerWegscheider et al. 2010; Davis et al. 2013; Gupta et al. 2013; Teh et al. 2013) , the majority prefer intravitreal injections, perhaps because these patients are expected to require fewer injections compared to HIV-positive patients due to expectance of immune recovery following cessation of their immunosuppressant drugs, or transient effect of local immunosuppression (Jeon & Lee 2015) .
Miao et al. (Miao et al. 2013 ) attempted to evaluate the efficacy and safety of multiple intravitreal injections of ganciclovir in a retrospective series of 14 patients treated for CMVR after HSCT. Injections were initiated upon CMVR diagnosis and were administered at weekly intervals. Systemic use of antiviral drugs was not given. They report that at one-month follow-up, CMV was not detected in 18 (78.3%) eyes, and all patients experienced diminished area of the lesion; 34.8% of eyes experienced VA improvement at 2 months of follow-up, yet 13% incurred very severe visual loss (due to retinal detachment or epiretinal haemorrhage). Overall, best corrected visual acuity (BCVA) did not improve significantly. No severe complications, including endophthalmitis, cataract or subretinal haemorrhage, were noted. Their results suggest that multiple intravitreal injections of ganciclovir could safely reduce levels of CMV in eyes with CMVR after HSCT (Miao et al. 2013) .
Recently, Jeon & Lee (2015) reported the safety and efficacy of intravitreal ganciclovir injections combined with systemic antiviral treatment in nine Korean HIV-negative patients with CMVR. During the induction period, the affected eyes received twice a week intravitreal injections of ganciclovir (2 mg/100 mL) until all lesions seemed inactive. The eyes then received weekly injections of ganciclovir as maintenance therapy until granular atrophy of the retinal lesions was noted without evidence of progression. The patients received a median number of 10 injections (range, 2-22 injections) during follow-up. Other than two cases of cataract, no serious complications (macular ischaemia, endophthalmitis, vitreous haemorrhage or ocular hypertension) were found to be associated with intravitreal ganciclovir injections (Jeon & Lee 2015) .
Systemic antiviral treatment was initiated concomitantly and consisted of ganciclovir (5 mg/kg twice daily) or valganciclovir (900 mg/daily) for at least 1 week. In cases of neutropenia, ganciclovir was switched to foscarnet (60 mg/kg, three times per day or 90 mg/kg twice a day). Patients who additionally had renal impairment were removed from all systemic treatment, but continued to receive intravitreal ganciclovir. The median durations of systemic ganciclovir, foscarnet and valganciclovir treatment were 8 (range, 3-26; 13 patients), 11 (range, 6-30; four patients) and 22 (range, 13-41; two patients) days, respectively.
Their outcomes show that the retinal lesions in all eyes stopped progressing and showed evidence of regression within 1-2 weeks following treatment. Following resolution of CMVR, there were five (22%) eyes with a VA ≤20/50. However, all of the eyes showed either unchanged BCVA or ≥2 lines improvement at the last visit. A significant improvement in the median BCVA was detected at the final visit (median BCVA of 20/50 at baseline, and 20/25 at final visit). Final VA was found to be associated with initial VA. No evidence of CMVR relapse was found in either the study eye or fellow eye during the follow-up period of at least one year (Jeon & Lee 2015) .
Also, Iu et al. (2016) recently described the outcome of combined systemic (intravenous ganciclovir, intravenous foscarnet or oral valganciclovir) and intravitreal (ganciclovir and/or foscarnet) anti-CMV therapy in 13 HIV-negative patients with CMVR. The mean duration of systemic therapy was 12 weeks (range, 0.6-19.3 weeks) . Patients received regular intravitreal injections of ganciclovir and/or foscarnet at a frequency of once to twice weekly. The mean duration of intravitreal injections was 6.5 weeks (range, 0.1-23.7 weeks), and the mean number of intravitreal injections was 9 (range, 1-33). No progression was observed and the retinitis resolved after initiation of treatment. Nevertheless, in one-third of the eyes, there was recurrence of CMVR, at a mean time of 6.4 weeks (range, 2.7-10.4 weeks) after discontinuation of therapy. Duration of systemic or intravitreal therapy, number of intravitreal injections, severity of vitreous haze and extent of retinitis were not associated with risk of recurrence. A quarter of the eyes developed retinal detachment (21.7% per eyeyear); 60% of the patients had final VA <20/70 and 35% had final VA <20/ 400. Poor presenting VA <20/70 was significantly associated with final VA <20/70, and final VA <20/400. Macular involvement was significantly and highly associated with final VA <20/ 400.
A report of non-HIV-related CMVR in four children and young adults (ages 12-23) (Samia et al. 2014 ) concluded that intravitreal therapy was better tolerated and more successful in treating the disease in this patient population. However, the intravitreal modality was only employed as the second or third treatment line, following lack of sufficient response to initial intravenous antiviral therapy (Samia et al. 2014) .
Our treatment approach is similar to these recently reported interventional series, and as previously presented (Vishnevskia-Dai et al. 2015 ) is herein summarized in Box 2. We believe that the optimal treatment strategy should combine the treatment alternatives (antiviral agent as well as administration), while the majority of previously reported treatment approaches were more conservative (Song et al. 2008; Jeon et al. 2012; Miao et al. 2013; Samia et al. 2014 ) (see Tables S1 and S2) .
Based on our experience (Vishnevskia-Dai et al. 2015) , prompt administration of intravitreal foscarnet and/or ganciclovir repeated over a short period may be warranted when the disease is located in the macula or near the optic disc. It should be given concomitantly with systemic antiviral treatment in case systemic involvement is suspected, particularly in immunocompromised patients with CMV viremia, suggesting the possibility of other CMV end-organ disease or fellow eye involvement. In our series, this aggressive treatment strategy has resulted in improvement of CMVR in all cases. Notwithstanding, the ultimate outcome in several cases was unsurprisingly related to the morbid systemic state and eventual expiry (VishnevskiaDai et al. 2015) .
Conclusions
In recent years, there is an increasing number of reports of CMVR in patients without HIV and including the paediatric population. It is now linked with multiple systemic morbidities ranging from apparent normal immune function, through conditions rendering limited immune dysfunction and finally severe immune dysfunction (Box 1). Type 2 diabetes, and particularly the related ocular steroids administration, seems to confer major risk for CMVR. We advise that in such complex patients, which are mostly in a transient immunosuppressed state, a high level of clinical suspicion should be practiced utilizing systemic evidence (e.g. CMV viremia) readily available in the multidisciplinary scenario and ocular periodic screening. Definite diagnosis may rely on the safer aqueous rather than on a vitreous tap approach.
Finally, others (Jeon & Lee 2015; Iu et al. 2016 ) and our (Vishnevskia-Dai et al. 2015) experience may suggest an aggressive treatment approach in the non-HIV-related severe CMVR cases (Box 2), entailing combination of antiviral agents, as well as combining delivery modalities (i.e. intravenous and intravitreal). Clearly, larger prospective trials are warranted to validate the suggested treatment strategy.
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